Metastatic malignant neoplasm

Summary

Metastatic malignant neoplasm (MONDO:0024880) is a cancer (an umbrella term covering 7 Mondo subtypes) and 676 clinical trials. Top therapeutic interventions include leucovorin, irinotecan, and talc anhydrous. A subtype of secondary malignant neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Umbrella term: 7 Mondo subtypes
• Clinical trials: 676

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	metastatic malignant neoplasm
Mondo ID	MONDO:0024880
ICD-11	1399468320
NCIT	C36263
UMLS	C2939419
MedGen	422475
Is cancer (heuristic)	yes

Also known as: malignant metastatic neoplasm · metastatic cancer · metastatic malignant neoplasm · metastatic neoplasm, malignant

Disease family

This is a subtype of secondary malignant neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › secondary malignant neoplasm › metastatic malignant neoplasm

Related subtypes (1): secondary carcinoma

Subtypes (7): metastatic carcinoma, metastatic malignant neoplasm in the colon, metastasis from malignant tumor of colon, metastatic malignant neoplasm in the spinal cord, metastatic malignant neoplasm in the eye, neoplastic meningitis, metastatic malignant neoplasm in the brain

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 676.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	185
Not specified	175
PHASE1	172
PHASE1/PHASE2	69
PHASE3	56
PHASE2/PHASE3	9
EARLY_PHASE1	8
PHASE4	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01348048	PHASE4	COMPLETED	A Trial Investigating the Effect of Specialised Palliative Care on Symptoms, Survival, Economical Factors and Satisfaction
NCT02000739	PHASE4	WITHDRAWN	Genetically-informed Therapies for Patients With Metastatic Cancer
NCT01592968	PHASE3	ACTIVE_NOT_RECRUITING	Stereotactic Radiosurgery or Whole Brain Radiation Therapy in Treating Patients With Newly Diagnosed Non-melanoma Brain Metastases
NCT02491632	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	Physical Activity and Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Advanced Cancer
NCT03021486	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recurrent Cancer
NCT03525873	PHASE3	ACTIVE_NOT_RECRUITING	A Study of Cancer Related Fatigue in Patients With Metastatic Cancer Receiving Anti-PD1 Immunotherapy
NCT03743649	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care
NCT05208047	PHASE3	ACTIVE_NOT_RECRUITING	(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
NCT05352178	PHASE3	RECRUITING	Metastasis-directed Therapy for Oligorecurrent Prostate Cancer
NCT06085716	PHASE2/PHASE3	RECRUITING	Combination Therapy for Cancer Related Fatigue in Patients With Metastatic Cancers
NCT06174987	PHASE3	RECRUITING	A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)
NCT06275958	PHASE3	RECRUITING	DOSAGE Study: Upfront Dose-Reduced Chemotherapy in Older Patients with Metastatic Colorectal Cancer
NCT06346197	PHASE3	RECRUITING	Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas
NCT06506955	PHASE2/PHASE3	ENROLLING_BY_INVITATION	Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.
NCT00002503	PHASE3	COMPLETED	Strontium Compared With Radiation Therapy in Treating Patients With Hormone-Refractory Prostate Cancer With Painful Bone Metastases
NCT00002622	PHASE3	COMPLETED	Talc in Treating Patients With Malignant Pleural Effusion
NCT00002692	PHASE3	UNKNOWN	Intravenous Compared With Intrahepatic Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver
NCT00002708	PHASE3	COMPLETED	Radiation Therapy With or Without Radiosurgery in Treating Patients With Brain Metastases
NCT00002716	PHASE3	COMPLETED	Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer
NCT00002764	PHASE3	COMPLETED	Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma
NCT00002793	PHASE3	UNKNOWN	Chemotherapy Via an Implantable Pump Compared With a Subcutaneous Port for Unresectable Liver Metastases in Patients With Resected Colorectal Cancer
NCT00002872	PHASE3	COMPLETED	Bleomycin, Doxycycline, or Talc in Treating Patients With Malignant Pleural Effusions
NCT00002899	PHASE3	TERMINATED	Adjuvant Radiation Therapy in Treating Patients With Brain Metastases
NCT00003162	PHASE3	COMPLETED	Radiation Therapy in Treating Patients With Bone Metastases From Breast or Prostate Cancer
NCT00003563	PHASE3	COMPLETED	Radiation Therapy Plus Gadolinium Texaphyrin in Treating Patients With Brain Metastases
NCT00003724	PHASE3	COMPLETED	Conventional or Video-Assisted Surgery in Treating Patients With Lung Metastases
NCT00003884	PHASE3	COMPLETED	Zoledronate in Treating Patients With Solid Tumors That Have Spread to the Bone
NCT00003941	PHASE3	COMPLETED	Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Men With Previously Untreated Germ Cell Cancer
NCT00005887	PHASE3	COMPLETED	Radiation Therapy With or Without RSR13 in Treating Patients With Brain Metastases
NCT00006479	PHASE3	UNKNOWN	Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer
NCT00020501	PHASE3	COMPLETED	Chemotherapy With or Without Isolated Hepatic Perfusion With Melphalan in Treating Patients With Colorectal Cancer That Has Spread to the Liver
NCT00020839	PHASE3	TERMINATED	Temozolomide With or Without Radiation Therapy to the Brain in Treating Patients With Stage IV Melanoma That Is Metastatic to the Brain
NCT00023868	PHASE3	TERMINATED	Combination Chemotherapy With or Without Chemoembolization in Treating Patients With Colorectal Cancer Metastatic to the Liver (6655)
NCT00030628	PHASE3	COMPLETED	Radiosurgery With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
NCT00039234	PHASE3	UNKNOWN	Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver
NCT00042770	PHASE3	COMPLETED	Standard Chest Tube Compared With a Small Catheter in Treating Malignant Pleural Effusion in Patients With Cancer
NCT00072020	PHASE3	UNKNOWN	Chemotherapy and/or Hormone Therapy With or Without Zoledronate in Treating Women With Stage II or Stage III Breast Cancer
NCT00079001	PHASE3	COMPLETED	Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases
NCT00082927	PHASE3	COMPLETED	Single-Dose Local Radiation Therapy Compared With Ibandronate in Treating Patients With Localized Metastatic Bone Pain
NCT00110123	PHASE3	TERMINATED	Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With Unresectable Liver Metastases From Eye Melanoma

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
LEUCOVORIN	4	37
IRINOTECAN	4	17
TALC ANHYDROUS	4	12
FLOXURIDINE	4	11
IBANDRONIC ACID	4	10
ZOLEDRONIC ACID ANHYDROUS	4	10
ADAGRASIB	4	6
MITOMYCIN	4	5
OXALIPLATIN	4	4
PANITUMUMAB	4	4
SUNITINIB MALATE	4	4
CEMIPLIMAB	4	3
FLUOROURACIL	4	3
NIRAPARIB	4	3
STRONTIUM CHLORIDE SR 89	4	3
VEMURAFENIB	4	3
BLEOMYCIN SULFATE	4	2
CALCIUM	4	2
CAPECITABINE	4	2
CRIZOTINIB	4	2
DOSTARLIMAB	4	2
ERLOTINIB	4	2
FILGRASTIM	4	2
FUTIBATINIB	4	2
HALOPERIDOL	4	2
IFOSFAMIDE	4	2
IMATINIB MESYLATE	4	2
MELPHALAN	4	2
MORPHINE SULFATE	4	2
OCTREOTIDE ACETATE	4	2